Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions

European Journal of Neurology

Volumn 18, Issue 4, 2011, Pages 571-576

  Bernecker, C ^a   Pailer, S ^a   Kieslinger, P ^a   Horejsi, R ^a   Moller R ^a   Lechner, A ^a   Wallner Blazek, M ^a   Weiss, S ^a   Fazekas, F ^a   Truschnig Wilders, M ^a   Gruber, H J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Hyperinsulinemia; Matrix metalloproteinases; Migraine; Tissue inhibitors of metalloproteinases

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GELATINASE A; GELATINASE B; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERSTITIAL COLLAGENASE; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; OXIDIZED LOW DENSITY LIPOPROTEIN; RESISTIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROPATHOLOGY; OBESITY; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERINSULINISM; LIPIDS; MALE; MATRIX METALLOPROTEINASES; MIGRAINE DISORDERS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79952731303     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03205.x     Document Type: Article

References (37)

1. Yong VW, Agrawal SM, Stirling DP. Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 2007; 4: 580-589.
2. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998; 21: 75-80.
3. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6: 480-498.
4. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007; 85: 2813-2823.
5. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
6. Yong VW. The potential use of MMP inhibitors to treat CNS diseases. Expert Opin Investig Drugs 1999; 8: 255-268.
7. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999; 2: 191-197.
8. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001; 36: 249-257.
9. Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J. Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia 2009 [Epub ahead of print].
10. Martins-Oliveira A, Speciali JG, Dach F, et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 2009; 408: 60-64.
11. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7: 354-361.
12. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003; 4: 386-398.
13. Schott GD. Exploring the visual hallucinations of migraine aura: the tacit contribution of illustration. Brain 2007; 130: 1690-1703.
14. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007; 13: 39-44.
15. Lauritzen M, Olsen TS, Lassen NA, Paulson OB. Regulation of regional cerebral blood flow during and between migraine attacks. Ann Neurol 1983; 14: 569-572.
16. Sanchez-del-Rio M, Reuter U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 2004; 17: 289-293.
17. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-142.
18. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004; 113: 1447-1455.
19. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 2006; 23: 87-96.
20. Rosenberg GA, Cunningham LA, Wallace J, et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 2001; 893: 104-112.
21. Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 2008; 48: 135-139.
22. Leira R, Sobrino T, Rodriguez-Yanez M, Blanco M, Arias S, Castillo J. Mmp-9 immunoreactivity in acute migraine. Headache 2007; 47: 698-702.
23. Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010; 74: 628-635.
24. Gruber HJ, Bernecker C, Pailer S, et al. Hyperinsulinaemia in migraineurs is associated with nitric oxide stress. Cephalalgia 2010; 30: 593-598.
25. Gruber HJ, Bernecker C, Pailer S, et al. Lipid profile in normal weight migraineurs - evidence for cardiovascular risk. Eur J Neurol 2010; 17: 419-425.
26. Guldiken B, Guldiken S, Taskiran B, et al. Migraine in metabolic syndrome. Neurologist 2009; 15: 55-58.
27. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006; 296: 283-291.
28. Goncalves FM, Jacob-Ferreira AL, Gomes VA, et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009; 403: 173-177.
29. Boden G, Song W, Kresge K, Mozzoli M, Cheung P. Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors. Am J Physiol Endocrinol Metab 2008; 295: E692-E697.
30. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004; 24(Suppl. 1): 9-160.
31. Derosa G, Maffioli P, D'Angelo A, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 2009; 32: E124-E132.
32. Muzzio ML, Miksztowicz V, Brites F, et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009; 40: 48-53.
33. Jong GP, Wang YF, Tsai FJ, et al. Immunoglobulin E and matrix metalloproteinase-9 in patients with different stages of coronary artery diseases. Chin J Physiol 2007; 50: 277-282.
34. Lehrke M, Greif M, Broedl UC, et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol 2009; 8: 50.
35. Boden G, Song WW. Effects of insulin and free fatty acids on matrix metalloproteinases. Curr Diab Rep 2008; 8: 239-242.
36. Schram K, Wong MM, Palanivel R, No EK, Dixon IM, Sweeney G. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J Mol Cell Cardiol 2008; 44: 874-881.
37. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006; 70: 146-157.